Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of BPSC1001 Ebola vaccine in healthy volunteers
PACTR201411000919191Phase 1Unknown
- Sponsor
- University Hospital Tübingen
- Start
- Nov 2014
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD), sponsored by University Hospital Tübingen. Primary endpoint: Safety and tolerability. Status: unknown.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR201411000919191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201411000919191.